(NewsDirect)
Futura Medical PLC (AIM:FUM, OTC:FAMDF)CEO James Barder speaks to Thomas Warner from Proactive London afterthe pharmaceutical company announced its interim results for the sixmonths to 30 June 2023.
Barder givesan overview of what he describes as a "pretty tremendous 2023 forFutura so far", highlighting the progress made in multiple marketswith the company's topical erectile dysfunction treatmentMED3000.
He starts with a look atthe enormously prospective US market where Futura secured both FDAapproval for the product as well as a distribution deal with Haleon,who are responsible for the future launch and ongoing regulatory,development, marketing, and commercialisation of MED3000 in theUSA.
Barder also talks about thestrides the company made in Europe during the first half and notedminimal complaints with over 200,000 packs sold.
Financially, the company reported £1.7million in revenue and a gross profit of £900,000, with Barder sayingthat he expects Futura to reach breakeven in 2024 and "is on trackfor a profit by 2025".
Barder acknowledged the importance ofproduction expansion to meet rising demand and highlighted efforts tostrengthen distribution networks, particularly in Asia.
Contact Details
Proactive UK Ltd
+44 207989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.